Optimizing platelet inhibition in peripheral artery disease: A comparison of mono-antiplatelet therapy and dual-antiplatelet therapy using thromboelastography
CONCLUSIONS: Patients on DAPT showed a significant increase in platelet inhibition when compared to initial aspirin MAPT. A significant difference in AA %platelet inhibition was shown for patients on DAPT when compared to initial clopidogrel MAPT. The results show that patients may benefit from DAPT post-revascularization. Personalizing antiplatelet therapy with objective viscoelastic testing to confirm adequate treatment may be the next step in optimizing patient outcomes to reduce thrombosis in PAD patients.PMID:38441042 | DOI:10.1177/17085381241237005 (Source: Vascular)
Source: Vascular - March 5, 2024 Category: Surgery Authors: Ivy Lee Sasha Suarez Ryan Hall Monica Majumdar Tiffany Bellomo Samuel Jessula Kathryn Nuzzolo Douglas M Jefferson Nikolaos Zacharias Anahita Dua Source Type: research
Clopidogrel versus newer P2Y12 inhibitors in the dual antiplatelet therapy for stent-assisted coil embolization of intracranial aneurysms: A meta-analysis
CONCLUSION: In patients who underwent a SACE, newer P2Y12 inhibitors showed no differences in intraoperative and follow-up complications compared with clopidogrel.PMID:38439698 | DOI:10.1177/15910199241236821 (Source: Interventional Neuroradiology)
Source: Interventional Neuroradiology - March 5, 2024 Category: Radiology Authors: S ávio Batista Raphael Camerotte Agostinho C Pinheiro Igor Costermani Anthony Bishay Jos é Alberto Almeida Filho Lucca B Palavani Edmundo Damiani Bertoli Raphael Bertani Jason A Ellis Yafell Serulle Christian Ferreira Source Type: research
Single antiplatelet therapy following Amplatzer left atrial appendage occlusion
CONCLUSIONS: SAPT following Amplatzer LAAO displayed rates of DRT and stroke comparable to those reported with more intensive antithrombotic regimens. Meanwhile, we observed low rates of major bleeding.PMID:38436367 | DOI:10.4244/EIJ-D-23-00684 (Source: EuroIntervention)
Source: EuroIntervention - March 4, 2024 Category: Cardiovascular & Thoracic Surgery Authors: Anders Kramer Kasper Korsholm Jens Erik Nielsen-Kudsk Source Type: research
Single antiplatelet therapy following Amplatzer left atrial appendage occlusion
CONCLUSIONS: SAPT following Amplatzer LAAO displayed rates of DRT and stroke comparable to those reported with more intensive antithrombotic regimens. Meanwhile, we observed low rates of major bleeding.PMID:38436367 | PMC:PMC10905198 | DOI:10.4244/EIJ-D-23-00684 (Source: EuroIntervention)
Source: EuroIntervention - March 4, 2024 Category: Cardiovascular & Thoracic Surgery Authors: Anders Kramer Kasper Korsholm Jens Erik Nielsen-Kudsk Source Type: research
Clopidogrel with indobufen or aspirin in minor ischemic stroke or high-risk transient ischemic attack: a randomized controlled clinical study
Ischemic stroke and transient ischemic attack (TIA) are the most prevalent cerebrovascular diseases. The conventional antiplatelet drugs are associated with an inherent bleeding risk, while indobufen is a new ... (Source: BMC Neurology)
Source: BMC Neurology - March 1, 2024 Category: Neurology Authors: Xudong Liu, Xuxian Lv, Yanfang Peng, Jianing Wang, Junjie Lei, Chaogang Tang, Shijian Luo, Weihua Mai, Yiming Cai, Qian Fan, Chenhao Liu and Lei Zhang Tags: Research Source Type: research
The pharmaco-epigenetics of hypertension: a focus on microRNA
Mol Cell Biochem. 2024 Feb 29. doi: 10.1007/s11010-024-04947-9. Online ahead of print.ABSTRACTHypertension is a major harbinger of cardiovascular morbidity and mortality. It predisposes to higher rates of myocardial infarction, chronic kidney failure, stroke, and heart failure than most other risk factors. By 2025, the prevalence of hypertension is projected to reach 1.5 billion people. The pathophysiology of this disease is multifaceted, as it involves nitric oxide and endothelin dysregulation, reactive oxygen species, vascular smooth muscle proliferation, and vessel wall calcification, among others. With the advent of ne...
Source: Molecular and Cellular Biochemistry - February 29, 2024 Category: Biochemistry Authors: Serge Yaacoub Ammar Boudaka Ali AlKhatib Gianfranco Pintus Amirhossein Sahebkar Firas Kobeissy Ali H Eid Source Type: research
Mechanistic Determinants of Daprodustat Drug-Drug Interactions and Pharmacokinetics in Hepatic Dysfunction and Chronic Kidney Disease: Significance of OATP1B-CYP2C8 Interplay
Clin Pharmacol Ther. 2024 Feb 26. doi: 10.1002/cpt.3215. Online ahead of print.ABSTRACTDaprodustat is the first oral hypoxia-inducible factor prolyl hydroxylase inhibitor approved recently for the treatment of anemia caused by chronic kidney disease (CKD) in adults receiving dialysis. We evaluated the role of organic anion transporting polypeptide (OATP)1B-mediated hepatic uptake transport in the pharmacokinetics (PKs) of daprodustat using in vitro and in vivo studies, and physiologically-based PK (PBPK) modeling of its drug-drug interactions (DDIs) with inhibitor drugs. In vitro, daprodustat showed specific transport by O...
Source: Clinical Pharmacology and Therapeutics - February 26, 2024 Category: Drugs & Pharmacology Authors: Yi-An Bi Samantha Jordan Amanda King-Ahmad Mark A West Manthena V S Varma Source Type: research
Mechanistic Determinants of Daprodustat Drug-Drug Interactions and Pharmacokinetics in Hepatic Dysfunction and Chronic Kidney Disease: Significance of OATP1B-CYP2C8 Interplay
Clin Pharmacol Ther. 2024 Feb 26. doi: 10.1002/cpt.3215. Online ahead of print.ABSTRACTDaprodustat is the first oral hypoxia-inducible factor prolyl hydroxylase inhibitor approved recently for the treatment of anemia caused by chronic kidney disease (CKD) in adults receiving dialysis. We evaluated the role of organic anion transporting polypeptide (OATP)1B-mediated hepatic uptake transport in the pharmacokinetics (PKs) of daprodustat using in vitro and in vivo studies, and physiologically-based PK (PBPK) modeling of its drug-drug interactions (DDIs) with inhibitor drugs. In vitro, daprodustat showed specific transport by O...
Source: Clinical Pharmacology and Therapeutics - February 26, 2024 Category: Drugs & Pharmacology Authors: Yi-An Bi Samantha Jordan Amanda King-Ahmad Mark A West Manthena V S Varma Source Type: research
Impact of hemodialysis on efficacies of the antiplatelet agents in coronary artery disease patients complicated with end-stage renal disease
AbstractIt is controversial whether hemodialysis affects the efficacy of the antiplatelet agents. We aimed to investigate the impact of hemodialysis on efficacies of the antiplatelet agents in coronary artery disease (CAD) patients complicated with end-stage renal disease (ESRD). 86 CAD patients complicated with ESRD requiring hemodialysis were consecutively enrolled. After 5-day treatment with aspirin and clopidogrel or ticagrelor, the platelet aggregations induced by arachidonic acid (PLAA) or adenosine diphosphate (PLADP), and the P2Y12 reaction unit (PRU) were measured before and after hemodialysis. The propensity matc...
Source: Journal of Thrombosis and Thrombolysis - February 23, 2024 Category: Hematology Source Type: research
Among patients with mild ischemic stroke or high-risk TIA, does combined clopidogrel-aspirin therapy initiated within 72hours after stroke onset and given for 21 days reduce the recurrence of stroke at 90 days compared to aspirin alone, and is it safe?
Rev Med Interne. 2024 Feb 21:S0248-8663(24)00056-0. doi: 10.1016/j.revmed.2024.02.002. Online ahead of print.NO ABSTRACTPMID:38388304 | DOI:10.1016/j.revmed.2024.02.002 (Source: Revue de Medecine Interne)
Source: Revue de Medecine Interne - February 22, 2024 Category: Internal Medicine Authors: L Lanthier M- É Plourde M Cauchon Source Type: research
Real-World Comparison of Clopidogrel with Ticagrelor and Prasugrel In Patients with Chronic Coronary Disease Undergoing Atherectomy
Current societal guidelines reserve potent P2Y12 platelet receptor inhibitors (ticagrelor, prasugrel) for acute coronary syndrome (ACS) cases due to a paucity of evidence for their use in chronic coronary disease (CCD).1 Patients with CCD undergoing percutaneous coronary intervention (PCI) with adjunctive atherectomy represent a subset of patients with more complex coronary disease who may derive benefit from more potent platelet inhibition.2 Atherectomy is associated with an increased risk of microvascular injury, endothelial dysfunction, and platelet activation, which may contribute to the increased risk of thrombosis, m...
Source: The American Journal of Cardiology - February 22, 2024 Category: Cardiology Authors: Mahin R. Khan, Anoop N. Koshy, Richard Tanner, Serdar Farhan, Manish Vinayak, Ali Farooq, Samantha Sartori, Yihan Feng, Alessandro Spirito, Ayush Arora, Vishal Dhulipala, Vishal Kapur, Javed Suleman, Raman Sharma, Roxana Mehran, Annapoorna Kini, Samin K. Tags: Brief report Source Type: research
The effects of CYP2C19 genotype polymorphism and clopidogrel resistance on ischemic event occurrence in patients with peripheral arterial disease undergoing revascularization: A prospective cohort study
Peripheral arterial disease (PAD) affects approximately 236 million people worldwide. Therefore, this study aimed to investigate the relationship between CYP2C19 genotype polymorphisms and clopidogrel resistance (CR) following revascularization in patients with PAD. (Source: Thrombosis Research)
Source: Thrombosis Research - February 16, 2024 Category: Hematology Authors: Yongkang Zhang, Qingzhi Ran, Kangli Yin, Yinkai Wang, Jiarui Liu, Yuan Zong, Yuzhen Wang, Yemin Cao Tags: Full Length Article Source Type: research
